Erich Schlick
Chairman
management team
Sensimed
Switzerland
Biography
Erich Schlick is general partner with Wellington Partners in Munich. Prior to venture capital, Erich spent 15 years with BASF Pharma Knoll AG, of which 10 years as an executive board member with worldwide responsibility for preclinical and clinical R&D. During this time, he obtained worldwide registrations for five products in cardiovascular, metabolic and pain indications. In 1993, he established the partnership with Cambridge Antibody Technology (CAT), which led to the successful development of Humira. Erich studied medicine and specialised in pharmacology. He holds a professorship of immunopharmacology at the University of Heidelberg/Mannheim.
Research Interest
CARDIOLOGY
